Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04485286 |
Recruitment Status :
Recruiting
First Posted : July 24, 2020
Last Update Posted : May 3, 2023
|
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | July 21, 2020 | ||||||||
First Posted Date ICMJE | July 24, 2020 | ||||||||
Last Update Posted Date | May 3, 2023 | ||||||||
Actual Study Start Date ICMJE | July 19, 2020 | ||||||||
Estimated Primary Completion Date | May 2027 (Final data collection date for primary outcome measure) | ||||||||
Current Primary Outcome Measures ICMJE |
Ability of [68Ga]CBP8 to detect collagen deposition in areas of radiation injury. [ Time Frame: 3-6 Months ] Probe uptake will be measured in lung cancer or pancreatic cancer patients 1) prior to radiation therapy and 2) 3-6 months after radiation therapy. We expect [68Ga]CBP8 signal to be increased in post radiation measurements over pre-radiation measurements in areas of irradiated tissue. Furthermore we expect that these areas will go on to develop radiation fibrosis.
|
||||||||
Original Primary Outcome Measures ICMJE |
Ability of [68Ga]CBP8 to detect collagen deposition in areas of radiation injury. [ Time Frame: 3-6 Months ] Probe uptake will be measured in lung cancer patients 1) prior to radiation therapy and 2) 3-6 months after radiation therapy. We expect [68Ga]CBP8 signal to be increased in post radiation measurements over pre-radiation measurements in areas of irradiated lung. Furthermore we expect that these areas will go on to develop radiation fibrosis.
|
||||||||
Change History | |||||||||
Current Secondary Outcome Measures ICMJE | Not Provided | ||||||||
Original Secondary Outcome Measures ICMJE | Not Provided | ||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||
Descriptive Information | |||||||||
Brief Title ICMJE | Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury | ||||||||
Official Title ICMJE | Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury | ||||||||
Brief Summary | The goal of this study is to investigate the efficacy of [68Ga]CBP8 to detect collagen deposition in radiation induced tissue injury. | ||||||||
Detailed Description | Detailed Description: The investigators have developed [68Ga]CBP8, a gallium-68 labeled collagen binding PET imaging probe, which selectively binds collagen type I. Collagen deposition is a pivotal event in several human conditions including radiation induced lung injury and in response to radiation therapy in pancreatic cancer. The investigator's studies in murine models of lung injury including radiation induced lung injury showed that [68Ga]CBP8 binds collagen with high affinity and has excellent pharmacological and pharmacokinetic profiles with high target uptake and low retention in background tissues and organs. [68Ga]CBP8 was shown in a mouse model to be effective for detecting lung fibrosis. [68Ga]CBP8 showed high specificity for pulmonary fibrosis and high target:background ratios in diseased animals. In addition, [68Ga]CBP8 could be used to monitor response to treatment. Ex vivo analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) supported the animal findings. The investigators have conducted preliminary studies in humans with IPF and demonstrated a significant increase in [68Ga]CBP8 signal in subjects with IPF vs healthy controls. The investigators thus aim to evaluate [68Ga]CBP8 in human subjects with radiation induced lung injury and in patients undergoing radiation therapy for pancreatic cancer: To establish the ability of [68Ga]CBP8-PET to detect radiation-induced fibrosis in lung or pancreatic cancer patients through the course of disease development with repeated measures, and correlate signal with standard measures of radiation induced tissue injury such as HRCT or MRI. |
||||||||
Study Type ICMJE | Interventional | ||||||||
Study Phase ICMJE | Phase 2 | ||||||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Intervention Model Description: Eligible subjects planning on receiving radiation for lung cancer or pancreatic cancer will be enrolled to undergo imaging with the PET Probe [68Ga]CBP8. Masking: None (Open Label)Primary Purpose: Diagnostic |
||||||||
Condition ICMJE |
|
||||||||
Intervention ICMJE | Drug: [68Ga]CBP8
Up to 15 mCi of [68Ga]CBP8 will be administered to each subject. Each subject will undergo baseline imaging prior to radiation and again 3-6 months after radiation therapy.
|
||||||||
Study Arms ICMJE | Experimental: Lung Cancer or Pancreatic Cancer Subjects Undergoing Radiation Therapy
Lung cancer or pancreatic cancer patients will receive [68Ga]CBP8 and undergo PET imaging 1) prior to radiation therapy and 2) 3-6 months after radiation therapy
Intervention: Drug: [68Ga]CBP8
|
||||||||
Publications * |
|
||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status ICMJE | Recruiting | ||||||||
Estimated Enrollment ICMJE |
72 | ||||||||
Original Estimated Enrollment ICMJE |
40 | ||||||||
Estimated Study Completion Date ICMJE | July 2027 | ||||||||
Estimated Primary Completion Date | May 2027 (Final data collection date for primary outcome measure) | ||||||||
Eligibility Criteria ICMJE | Inclusion Criteria for lung cancer subjects:
Inclusion Criteria for pancreatic cancer subjects:
Exclusion Criteria for lung cancer subjects:
Exclusion Criteria for pancreatic cancer subjects:
|
||||||||
Sex/Gender ICMJE |
|
||||||||
Ages ICMJE | 18 Years to 80 Years (Adult, Older Adult) | ||||||||
Accepts Healthy Volunteers ICMJE | No | ||||||||
Contacts ICMJE |
|
||||||||
Listed Location Countries ICMJE | United States | ||||||||
Removed Location Countries | |||||||||
Administrative Information | |||||||||
NCT Number ICMJE | NCT04485286 | ||||||||
Other Study ID Numbers ICMJE | 2020P001899 R44CA250771 ( U.S. NIH Grant/Contract ) K08CA259626 ( U.S. NIH Grant/Contract ) |
||||||||
Has Data Monitoring Committee | Yes | ||||||||
U.S. FDA-regulated Product |
|
||||||||
IPD Sharing Statement ICMJE |
|
||||||||
Current Responsible Party | Peter Caravan, Massachusetts General Hospital | ||||||||
Original Responsible Party | Peter David Caravan, Massachusetts General Hospital, Professor of Radiology | ||||||||
Current Study Sponsor ICMJE | Massachusetts General Hospital | ||||||||
Original Study Sponsor ICMJE | Same as current | ||||||||
Collaborators ICMJE | National Cancer Institute (NCI) | ||||||||
Investigators ICMJE |
|
||||||||
PRS Account | Massachusetts General Hospital | ||||||||
Verification Date | April 2023 | ||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |